Table 3.
Operating Characteristics of Galactomannan Testing for Diagnosis of Proven or Probable Aspergillosisa in Pediatric Patients
| Author Year | Total No. Patients/Episodes in Study | Proven or Probable Aspergillosis | Sensitivity, % | Specificity, % | TP | FP | TN | FN | False-Positive Rate, %b |
|---|---|---|---|---|---|---|---|---|---|
| Hayden 2008 [15]c | 56 | 17 | 65 | 87 | 11 | 5 | 34 | 6 | 12.8 |
| Steinbach 2007 [10] | 64 | 1 | 0 | 87 | 0 | 8 | 55 | 1 | 12.7d |
| Hovi 2007 [8] | 89 | 1 | 100 | 93 | 1 | 6 | 82 | 0 | 6.8 |
| Sulahian 2001 [11] | 347 | 9 | 100 | 89.9 | 9 | 34 | 304 | 0 | 10.1 |
| Rohrlich 1996 [9] | 37 | 10 | 100 | 92.6 | 10 | 2 | 25 | 0 | 7.4 |
| Armenian 2009 [12] | 78 | 3e | 100 | 98.7 | 3e | 1 | 74 | 0 | 1.3 |
| Our Study | |||||||||
| Serum (threshold 0.5) | 195 | 1 | 0 | 95 | 0 | 10 | 184 | 1 | 5.2 |
| Urine (threshold 0.5) | 179 | 1 | 100 | 80 | 1 | 36 | 142 | 0 | 20.2 |
Abbreviations: FP, false positive; FN, false negative; TN, true negative; TP, true positive.
aThe definition of proven or probable aspergillosis varied depending on the publication.
bDefined as the number of false-positive results per total number of patients without IA.
cCase-control study design may inflate the calculated false-positive rate for this study.
dAfter accounting for piperacillin-tazobactam exposure, the false-positive rate was 8.5%.
eAll 3 probable cases required inclusion of positive GM EIA results to qualify for this designation.